Joint Commission of Pharmacy Practitioners MEMBER ORGANIZATION UPDATES ORGANIZATION: Academy of Managed Care Pharmacy Action Plan Implementation Activity JCPP Meeting – Feb 5, 2020 Pharmacists’ Patient Care Services AMCP held a series of webinars (November 2019-January 2020) on improving pharmacy care practice related to specific disease states and system operations, including: o o o o o o o o o o Nov 5: Guidelines – Antiviral Therapies for Influenza: What You Need to Know for 2019-2020 Nov 7: Biosimilars: Real World Considerations For Pharmacists Nov 12: Examining Latest Evidence for AMD (age-related macular degeneration) Treatment Nov 13: Data and Guidelines in Lipids for Therapeutic Selection and Patient Care Optimization Nov 14: Opioid Use Disorder: Best Practices for Payer/Clinician Management of Patient Care Nov 19: Real-World Applications of Clinical Trial Data and Changing Guidelines in IBD Dec 4: New Data/Guidelines in Lipids for Therapeutic Selection and Patient Care Optimization Dec 11: Switch or Not to Switch: Optimizing Treatment Decisions after Anti-TNF Failure in RA Jan 14: Optimizing Prior Authorization for Appropriate Medication Selection Jan 16: Data Drivers Fostering Innovations in Oncology – from AMCP Foundation Symposium JMCP (Jan2020) publishes A Pharmacist-Led, Patient-Centered Program Incorporating Motivational Interviewing for Behavior Change to Improve Adherence Rates and Star Ratings in a Medicare Plan The article examined Envolve Pharmacy Solutions’ pharmacist-led, patient-centered adherence program incorporating motivational interviewing (MI) for behavior change Research found this approach resulted in improved adherence rates in all therapeutic classes immediately Pharmacy Quality AMCP to participate in February workshop, “Understanding How the Public Perceives and Values Pharmaceutical Quality,” sponsored by the Duke Margolis Center for Health Policy, in partnership with the FDA The workshop offers opportunity to better understand how stakeholders — including patients, providers, pharmacists, drug purchasers, and payers — perceive and value the quality of pharmaceutical products Topics include: importance of pharmaceutical quality; the Page current state of pharmaceutical quality FDA’s role in regulating quality; stakeholder perceptions of pharmaceutical quality AMCP continues to play a leadership role in supporting Pharmacy Quality Alliance (PQA) AMCP CEO Susan A Cantrell recently was appointed to serve a second term on PQA’s board of directors Value of Pharmacists’ Patient Care Services JMCP (Jan2020) publishes Effect of a Virtual Pharmacy Review Program: A Population Health Case Study The article examines a population health management program that optimizes the pharmacist’s skills as a medication expert and available technology to allow for a broader patient reach The program demonstrated a pharmacist’s ability to achieve the desired outcomes of positively affecting clinical and cost-savings measures In the first full year of the program, fulltime pharmacist completed 871 previsit comprehensive medication review (pvCMRs), reviewed over 8,000 e-prescriptions, and made over 3,400 recommendations to improve medication use Health Information Technology AMCP created an education track on “Rx for Digital Therapeutics” at AMCP 2020 (April 21-24 in Houston, Texas) Track will include sessions on developing systems and processes that support digital therapeutic adoption and use, as well as defining managed care pharmacy’s role in how digital therapeutics fit into pharmacy and medical benefits AMCP CEO Susan A Cantrell was a panelist at the Jan 14 Digital Medicine & Medtech Showcase session on digital therapeutics, during JP Morgan’s Healthcare Conference in San Francisco Cantrell presented payer considerations on covering the innovative technologies AMCP continued its active support of the Pharmacy HIT Collaborative, serving as one of the organization’s strategic members Provider Status Recognition JMCP (Jan2020) publishes Financial Sustainability of an Oregon Rural Health, Primary Care, and Pharmacist-Run Comprehensive Medication Management Program Through Direct Medical Billing Article looks at whether direct billing of third-party payers covers the direct cost of a comprehensive medication management program in an ambulatory rural health adult population with uncontrolled diabetes or hypertension CONCLUSIONS: Pharmacist-run services within the rural health primary care clinics were not financially justifiable via direct billing of third-party payers alone The lack of credentialing, recognition of pharmacists as providers, and reimbursement is inadequate for program expansion and sustainability without relying on additional revenue streams or benefits from improved patient outcomes Currently, federal insurance significantly contributes to this lack of funding Organization Update (other information): AMCP Holds Jan 22 webinar on recent federal and state legislative/regulatory developments AMCP held a Dec 10-11, 2019 Partnership Forum that looked at ways to modernize the specialty pharmacy benefit for the 21st century Recommendations of diverse stakeholder participants included the need for increased simplicity in the benefit structure, broader financial risk sharing, and an enhanced focus on patient care AMCP rolled out Version 4.1 of the AMCP Format for Formulary Submissions, which includes two new dossier types for biopharmaceutical manufacturers to share evidence on unapproved products and new indications that are under review by the FDA Latest version of the Format will Page allow payers to provide faster access to the valuable, yet often expensive, therapies once they become available AMCP holds Jan 23 webinar on Version 4.1 JMCP marked its 25th anniversary in 2020 To commemorate this milestone, the publication will publish a series of articles that document the changes to the journal and profession over the past two and a half decades AMCP launched first AMCP Legislative Days Student Scholarship Student pharmacist recipients will join AMCP leaders and staff in advocating for managed care pharmacy priorities in offices of U.S Senators and Representatives on Legislative Days event, March 30-April AMCP Great Plains Affiliate is officially launched New affiliate comprises AMCP members from Kansas, Nebraska, Missouri, Iowa, North Dakota, and South Dakota who have desire for more education and networking at the local level Florida AMCP is formed New affiliate was formed to better serve the large number of managed care pharmacists and professionals in Florida with education and networking activities AMCP announced keynote speakers for AMCP 2020, April 21-24 in Houston, Texas They are: Dan Buettner, National Geographic Fellow, award-winning journalist and producer, and New York Times bestselling author; and Marty Makary, MD, member of National Academy of Medicine, and named one of America’s 20 most influential people in health care by Health Leaders magazine AMCP announced elected officers for upcoming Board of Directors They are: 2020-21 Presidentelect Paul L Jeffrey; 2020-22 Directors Jessica Daw; Pat Gleason; and Carly Rodriguez New Board members, along with those continuing service, will be sworn in at AMCP 2020 in Houston AMCP submitted a Dec 31, 2019, letter to HHS OIG on proposed changes to the federal antikickback statute AMCP expressed concern that proposed safe harbors will exclude key stakeholders — pharmaceutical manufacturers — from protection and limit the ability of covered stakeholders to provide meaningful value-based care AMCP submitted a Dec 16, 2019, letter to the House of Representatives regarding 21 st Century Cures Act, 2.0 AMCP’s comments focused on the need to codify into law existing FDA guidance on the communication of health care economic information (HCEI) as a means to improve access to innovative therapies AMCP also said it supports Cures 2.0’s focus on digital health, specifically as it relates to digital therapeutics (DTx) AMCP’s goal is to ensure that patients will have access to DTx that offer optimal clinical value at an affordable cost AMCP prepares comments on Trump administration’s Dec 18 notice of proposed rulemaking that would allow for the importation of certain prescription drugs from Canada AMCP also will comment on draft guidance that describes procedures for drug manufacturers to follow to facilitate importation of pharmaceuticals, including biological products, that are FDA-approved, manufactured abroad, authorized for sale in any foreign country, and originally intended for sale in that foreign country AMCP comments will be consistent with its position statement on Prescription Drug Importation JMCP added two academic health care researchers to JMCP’s editorial team Editors are: Carrie McAdam-Marx, Professor, Department of Pharmacy Practice and Science, University of Nebraska Medical Center College of Pharmacy; and Michael T Rupp, Professor of Pharmacy Administration, Midwestern University – Glendale, Ariz JMCP (Jan2020) publishes AMCP Partnership Forum: Principles for Sound Pharmacy and Therapeutics (P&T) Committee Practices: What’s Next? Article describes March 2019, Partnership Forum that included recommendations on: P&T committee composition and relevant stakeholders; evaluation of emerging evidence for formulary decisions and recommendations around training of P&T committee members, and; characteristics and best practices of successful committees JMCP (Jan2020) publishes AMCP Partnership Forum: Optimizing Prior Authorization for Appropriate Medication Selection Article describes June 2019 Partnership Forum that included recommendations: to improve efficiencies around PA and step-therapy processes; address Page administrative burdens; increase the visibility of the clinical and economic value of the utilization management programs; and improve channels of communications between health insurance providers, health care professionals, and patients to minimize care delays and improve clarity of coverage authorization requirements Cate Lockhart, PharmD, PhD, Executive Director at Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), participated in the Specialty Therapies and Biosimilars Congress, Jan 22-24, in Miami, Fla., including moderating a session on, Barriers to Entry — Challenges and Solutions for Entering the Marketplace